{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:47:47Z","timestamp":1772722067175,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>It has been proven that ALK\u2010rearranged non\u2010small cell lung cancer (NSCLC) is sensitive to ALK inhibitors while the chemotherapy resistance is unavoidable. In this study, safety and antitumor activity of the novel ALK inhibitor (ALKi) CT\u2010707 were evaluated in Chinese patients with advanced ALK\u2010rearranged NSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This single\u2010center, open\u2010label phase I study recruited adult patients with ALK\u2010rearrangement (confirmed by fluorescence in situ hybridization and\/or immunohistochemistry) of locally advanced\/metastatic malignancies including NSCLC. This study consisted of two parts: dose escalation and dose expansion. CT\u2010707 was administered orally once a day for 21\u2009days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 13 patients who were treated with CT\u2010707 from 450 to 600 mg (in the dose increasing phase) were enrolled in this trial (two patients were previously treated with crizotinib). There were 12 patients diagnosed with lung adenocarcinoma and one patient with malignant pleural mesothelioma. After treatment, grade 3 diarrhea (600 mg once a day) was found as dose\u2010limiting toxicity (DLT).The most common adverse events included diarrhea (92%), elevated aspartate aminotransferase (61%), elevated alanine aminotransferase (54%), hair loss (38%), and vomiting (31%). The overall response rate was 77% (10\/13). Among all patients, four of the five patients who did not receive any treatment, one of the two patients who had received treatments with crizotinib, and five of the six patients who received standard chemotherapy achieved partial response (PR). One patient reached a complete remission (CR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study indicated that CT\u2010707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement. It is safe and reliable and the dose\u2010expansion phase recruitment has started.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.13376","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T09:55:50Z","timestamp":1584438950000},"page":"1216-1223","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single\u2010center study to determine the safety and efficacy of CT\u2010707 in Chinese patients with advanced anaplastic lymphoma kinase\u2010rearranged non\u2010small\u2010cell lung cancer"],"prefix":"10.1111","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6316-5123","authenticated-orcid":false,"given":"Peng","family":"Song","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Science &amp; Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Science &amp; Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongliang","family":"Yang","sequence":"additional","affiliation":[{"name":"Cangzhou Medical College  Hebei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-2280","authenticated-orcid":false,"given":"Hanping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Science &amp; Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-3045","authenticated-orcid":false,"given":"Xiaoyan","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Science &amp; Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Science &amp; Peking Union Medical College  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8122112"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07261"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.03.012"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6993"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70344-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003316"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30123-X"},{"key":"e_1_2_7_11_1","first-page":"66","volume-title":"2014 Frontiers of Medical Sciences and the Third Symposium on New Trends in Individualized Therapy and Antitumor Drug Research","author":"Peng Y","year":"2015"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx671.023"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"#cr-split#-e_1_2_7_14_1.1","unstructured":"National Cancer Institute National Institutes of Health U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. [last accessed March 16 2015];NIH publication # 09-7473. Published May 29 2009"},{"key":"#cr-split#-e_1_2_7_14_1.2","unstructured":"Revised Version 4.03 June 14 2010. Available from URL:http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5\u00d77.pdf."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0282"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0251-8"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1515281112"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.05.002"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1759-7714.13376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.13376","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T10:32:32Z","timestamp":1756204352000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.13376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/1759-7714.13376"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.13376","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]},"assertion":[{"value":"2020-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}